CCTG Clinical Trials
Public Trial Select
Member Trial Select
International research collaboration explores blood-based biomarkerUsing non-invasive approaches to confirm POLE and POLD1 mutations in solid tumors and to investigate whether those tumors are responsive to immunotherapy. More >> |
Recently Activated Trials
Member Links
CCTG’s MA.39 trial receives green light from funding bodiesOne of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. More >> |
Planned Trials
Committees Select
Canadian Cancer Trials Group awarded $25 million in funding to support clinical trials
Bringing major cancer clinical trials to Canada through the US National Clinical Trials Network
The Canadian Cancer Trials Group (CCTG) has been awarded more than 19 million USD over six years (approximately $25 million CAD) from the U.S. National Institutes of Health (NIH) and National Cancer Institute (NCI). This award will allow the group to continue their work leading major cancer clinical trials in Canada through the US National Clinical Trials Network (NCTN) and to develop new large scale trials under CCTG leadership.
“The renewed funding will continue the US-Canadian research collaboration and allow CCTG to take the lead on a number of important trials over the next few years,” says Janet Dancey, Director of CCTG. “The partnership will support more rapid accrual to trials led by US-based groups who will be working alongside CCTG to identify better treatments for patients with cancer.”
More >>
CCTG CO26 is the first randomized trial to demonstrate immunotherapy benefit in patients with colorectal cancer
The ground breaking results of Canadian Cancer Trials Group (CCTG) CO.26 study were presented at the American Society of Clinical Oncology 2019 Gastrointestinal Cancers Symposium (ASCO GI).
More >>
Innovative study advances personalized medicine for prostate cancer patients
A new clinical trial, opening across Canada, is considered a major advancement in precision medicine for prostate cancer and the first of its kind in the world.
More >>
International research collaboration explores blood-based biomarker
Using non-invasive approaches to confirm POLE and POLD1 mutations in solid tumors and to investigate whether those tumors are responsive to immunotherapy.
More >>
2019 New Investigator Clinical Trials Course
2019 New Investigator Clinical Trials Course
Mark your calendars for the next CCTG New Investigator Clinical Trials Course (NICTC) being held August 7th to the 9th at the Donald Gordon Centre in Kingston, Ontario.
The NICTC is an important component of the group mandate to provide and facilitate investigator education and training. The major goal of this three-day course is to familiarize new investigators from across the country with the essentials of clinical trial conduct in the Canadian research environment.
More >>
The rise of precision medicine
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
More >>
Innovative study advances personalized medicine for prostate cancer patients
A new clinical trial, opening across Canada, is considered a major advancement in precision medicine for prostate cancer and the first of its kind in the world.
More >>Planned trials
CRC9
Circulating Tumor DNA as a Predictive Marker for Response to Chemotherapy in Pts with Stage II Colon Ca
Recently activated
The rise of precision medicine
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
More >>
TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancer
Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.
More >>
Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide
Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery. The randomized phase III clinical trial was sponsored by the academic cancer research groups of UNICANCER, in Paris, France and the Canadian Cancer Trials Group (CCTG). The results show that the risk of cancer recurring in post-operative pancreatic cancer patients was reduced by almost 50% with the mFOLFIRINOX chemotherapy combination.
More >>
New pancreatic cancer trial provides hope to BC family
An innovative clinical trial underway across Canada is providing new hope to a B.C. family braving pancreatic cancer – the deadliest cancer facing Canadians today.
More >>Publications
Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: a randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219 (ONLINE)
Lung Cancer , 2019
Melosky B;Bradbury P;Tu D;Florescu M;Reiman A;Nicholas G;Basappa N;Rothenstein J;Goffin JR;Laurie SA;Wheatley-Price P;Leighl N;Goss G;Reaume MN;Butts C;Murray N;Card C;Ko J;Blais N;Gray S;Lui H;Brown-Walker P;Kaurah P;Prentice LM;Seymour L;
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis
J Clin Oncol 37: 1102 - 1110, 2019
Litiere S;Isaac G;de Vries EGE;Bogaerts J;Chen A;Dancey J;Ford R;Gwyther S;Hoekstra O;Huang E;Lin N;Liu Y;Mandrekar S;Schwartz LH;Shankar L;Therasse P;Seymour L;
CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC)
J Clin Oncol 37, 2019
Chen EX;Jonker DJ;Kennecke HF;Berry SR;Couture F;Ahmad CE;Goffin JR;Kavan P;Harb M;Colwell B;Samimi S;Samson B;Abbas T;Aucoin N;Aubin F;Koski SL;Wei AC;Magoski NM;Tu D;O'Callaghan CJ;
LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/ Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer
Clin Lung Cancer 20: 66 - 73, 2019
Seymour L;Le Teuff G;Brambilla E;Shepherd FA;Soria JC;Kratzke R;Graziano S;Douillard JY;Rosell R;Reiman A;Lacas B;Lueza B;viel-Ronen S;McLeer A;Le Chevalier T;Pirker R;Filipits M;Dunant A;Pignon JP;Tsao MS;
Outcomes of Older Patients(>= 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20
Clinical Colorectal Cancer 18: e140 - e149, 2019
Wells JC;Tu D;Siu LL;Shapiro JD;Jonker DJ;Karapetis CS;Simes J;Liu G;Price TJ;Tebbutt NC;O'Callaghan CJ;
Pilot study of the ability to probabilistically link clinical trial patients to administrative data and determine long-term outcomes
Clinical Trials 16: 14 - 17, 2019
Hay AE;Pater JL;Corn E;Han L;Camacho X;O'Callaghan C;Chong N;Bell EN;Tu D;Earle CC;
Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis (ONLINE)
Leuk Lymphoma : 1 - 8, 2019
Al-Mansour Z;Cook JR;Constine LS;Couban S;Stewart DA;Shea TC;Porcu P;Winter JN;Kahl BS;Smith SM;Marcellus DC;Barton KP;Mills GM;LeBlanc M;Rimsza LM;Forman SJ;Leonard JP;Fisher RI;Friedberg JW;Stiff PJ;
Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218
Pediatr Blood Cancer 66: e27540, 2019
Deyell RJ;Wu B;Rassekh SR;Tu D;Samson Y;Fleming A;Bouffet E;Sun X;Powers J;Seymour L;Baruchel S;Morgenstern DA;